Product details
Background:Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer.
• Zinc and cancer: implications for LIV-1 in breast cancer., PMID:22852056
• Recombinant Expression of Zinc Transporter SLC39A6 and Its Functional Antibody Production., PMID:31009334
• Zip6 (LIV-1) regulates zinc uptake in neuroblastoma cells under resting but not depolarizing conditions., PMID:18272141
• A mechanism for epithelial-mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3)., PMID:23919497
• Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7., PMID:18330719
• Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells., PMID:19852955
• Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy., PMID:21862359






